Year archive

Isofol Medical — 2024 filings

All 42 regulatory filings released by Isofol Medical (ISOFOL) in 2024, sourced directly from the official regulator.

42 Filings

2024 Period

2024 filings (42)

Filing	Released	Lang
Isofol appoints nomination committee ahead of the Annual General Meeting 2025 Board/Management Information	2024-11-19	English
Isofol har utsett valberedningen inför årsstämman 2025 AGM Information	2024-11-19	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report 9M 2024	2024-11-12	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report 9M 2024	2024-11-12	English
Isofol stärker utsikterna för utökat patentskydd av läkemedelskandidaten arfolitixorin Regulatory Filings	2024-09-17	Swedish
Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin Regulatory Filings	2024-09-17	English
Isofol terminates liquidity guarantee agreement Regulatory Filings	2024-09-12	English
Isofol avslutar avtal om likviditetsgaranti Regulatory Filings	2024-09-12	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report H2 2024	2024-08-21	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report H2 2024	2024-08-21	Swedish
Isofol appoints Magdalena Hagman as new Chief Financial Officer Board/Management Information	2024-07-30	English
Isofol utser Margareta Hagman till ny Chief Financial Officer Board/Management Information	2024-07-30	Swedish
Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin Regulatory Filings	2024-07-16	English
Isofol meddelar att nya prekliniska data stöder den tidigare annonserade kliniska utvecklingsplanen för arfolitixorin Regulatory Filings	2024-07-16	Swedish
Isofol announces a post hoc per-protocol analysis of the AGENT study, further supporting arfolitixorin’s continued clinical development Investor Presentation	2024-07-05	English
Isofol meddelar att en post hoc-analys per protokoll av AGENT-studien ger ytterligare stöd för arfolitixorins fortsatta kliniska utveckling Regulatory Filings	2024-07-05	Swedish
Isofols Chief Financial Officer lämnar bolaget Board/Management Information	2024-06-12	Swedish
Isofol's Chief Financial Officer to leave the company Board/Management Information	2024-06-12	English
Isofol and Charité sign collaboration agreement on further clinical development of arfolitixorin Regulatory Filings	2024-05-24	English
Isofol och Charité har tecknat ett samarbetsavtal om vidare klinisk utveckling av arfolitixorin Regulatory Filings	2024-05-24	Swedish
Kommuniké från årsstämma i Isofol Medical AB (publ) den 8 maj 2024 AGM Information	2024-05-08	Swedish
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 8, 2024 AGM Information	2024-05-08	English
Interim / Quarterly Report 2024 Interim / Quarterly Report Q1 2024	2024-05-08	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report Q1 2024	2024-05-08	Swedish
Annual Report 2023 Annual Report FY 2023	2024-04-16	Swedish
Kallelse till årsstämma den 8 maj 2024 i Isofol Medical AB (publ) AGM Information	2024-04-05	Swedish
Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ) AGM Information	2024-04-05	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-03-20	English
Isofols japanska partner Solasia har beslutat att intensifiera sitt engagemang i den kliniska utvecklingen av arfolitixorin Regulatory Filings	2024-03-19	Swedish
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin Regulatory Filings	2024-03-19	English
Isofol presenterar en klinisk utvecklingsplan för arfolitixorin Investor Presentation	2024-03-19	Swedish
Isofol presents a clinical development plan for arfolitixorin Investor Presentation	2024-03-19	English
Interim / Quarterly Report 2023 Interim / Quarterly Report Q4 2023	2024-02-20	Swedish
Earnings Release 2023 Earnings Release Q4 2023	2024-02-20	Swedish
Styrelsen i Isofol inleder planeringen av kliniska studier och kommer att annonsera en strategisk utvecklingsplan den 19 mars Investor Presentation	2024-02-14	Swedish
Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19 Regulatory Filings	2024-02-14	English
Isofol appoints Magnus Hurst as new Chief Financial Officer Board/Management Information	2024-01-10	English
Isofol utser Magnus Hurst till ny Chief Financial Officer Board/Management Information	2024-01-10	Swedish
Isofol utser Petter Segelman Lindqvist till ny verkställande direktör Board/Management Information	2024-01-09	Swedish
Isofol appoints Petter Segelman Lindqvist as new CEO Board/Management Information	2024-01-09	English
Kommuniké från extra bolagsstämma i Isofol Medical AB (publ) den 4 januari 2024 AGM Information	2024-01-04	Swedish
Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024 AGM Information	2024-01-04	English